Lantos Technologies, a Cambridge, MA-based developer of an intra-aural 3D scanner, closed a $4.1m Series B financing.
The round was led by Excel Venture Management with participation from Catalyst Health Ventures, and Mass Medical Angels (all existing investors).
In September 2010, the company raised $1.6m in Series A funding (read here).
Lantos intends to use the funds to continue to develop its real-time 3D ear canal scanning technology which is designed to enable custom fit audio devices such as hearing aids, earphones and noise-canceling devices.
Discovered and developed in the lab of MIT professor Douglas Hart, the technology provides minimally invasive digital mapping of the human ear canal.
The company also appointed Jeffrey C. Leathe as CEO and Chairman of the Board of Directors. The founding CEO, Shahid Azim, becomes Senior Vice President, New Market Development, primarily focusing on consumer applications.
Before joining Lantos, Mr. Leathe was Chairman and CEO of Biocius Life Sciences, a privately held instrument and contract research organization focused on drug discovery research and clinical diagnostic testing.
FinSMEs
29/08/2011